(Q42791847)

7 November 2017

title

Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations (English)

1 reference

7 November 2017

0 references

1 reference

Ping C Bee

6

0 references

author name string

Gin Gin Gan

1

1 reference

7 November 2017

Maude E Phipps

2

1 reference

7 November 2017

Michael M T Lee

3

1 reference

7 November 2017

Liang S Lu

4

1 reference

7 November 2017

Rajallectchumy Y Subramaniam

5

1 reference

7 November 2017

Sean H Chang

7

1 reference

7 November 2017

publication date

26 November 2010

1 reference

7 November 2017

1 reference

7 November 2017

volume

90

1 reference

7 November 2017

issue

6

1 reference

7 November 2017

page(s)

635-641

1 reference

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

The influence of ethnicity on warfarin dosage requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Pharmacogenetics and anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Racial background is a determinant factor in the maintenance dosage of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Aging and the anticoagulant response to warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Genetic and clinical factors relating to warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Genetic influences on the response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Genetic determinants of warfarin dosing in the Han-Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Population variation in VKORC1 haplotype structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1119-6

10.1007/S00277-010-1119-6

21 January 2018

Identifiers

DOI

1 reference

release_6ifvouvq2fbm7ffd6eqa5upt4y

7 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6ifvouvq2fbm7ffd6eqa5upt4y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference